Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the…
News
EU clinical trial advice pilot becomes permanent
Endeavor’s Phase IIb IPF study of taladegib meets endpoints
Alpheus begins multi-centre study for butterfly GBM
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Dignify Therapeutics secures FDA clearance for Phase I DTI-117 trial
